

## Update from the Pharmaceutical Benefits Advisory Committee May 2026

The PBAC held a one day Intracycle Meeting on 8<sup>th</sup> May, 2026. This meeting covered 18 Agenda items, including a number of non-submission items to consider listing changes arising from recent commercial decisions of various Sponsors.

Other items on the agenda included matters related to a completed Post Market Review of Pulmonary Arterial Hypertension (PAH) medicines, and consideration of Designated Registered Nurse prescribing for several therapeutic groups of PBS medicines.

Outcomes from this PBAC meeting will be published on the PBS website on the **19 June 2026**.

### **Out-of-session work**

The PBAC out-of-session work for the Committee Chairs this period also included a number of meetings with stakeholders, including patient group representatives, clinical groups and industry representatives. Focus of discussions included:

- Revision of PBS listing arrangements to resolve unintended implementation barriers.
- Alignment of certain PBS restrictions with latest clinical consensus and practice.
- Broadening current listing arrangements to resolve unmet clinical need risks as some medicines are being removed from the PBS by the Sponsor.
- PBAC process and guidance advice.

Activities towards the end of May included preparation meetings before the ESC and DUSC sub-committee meetings being held through the week beginning 1 June. The sub-committee work is informed by a number of inputs, including consumer and clinical submissions provided through the Office of Health Technology Assessment (OHTA) consultation hub, patient group discussions, and expert clinical reviews, as required.

### **Upcoming PBAC meeting**

The next 3 day PBAC meeting is being held **8 – 10 July 2026**.

### **Professor Robyn Ward AM**

Chair, Pharmaceutical Benefits Advisory Committee

### **Ms Jo Watson**

Deputy Chair, Pharmaceutical Benefits Advisory Committee